Picton Mahoney Asset Management’s Japer Therapeutics Warrants JSPRW Stock Holding History
Bought
Maintained
Sold
Other funds holding JSPRW
OCAM
TCM
PSAMP
SCM
SRCM
AA
UOC
GCL
MS
BI
Picton Mahoney Asset Management's JSPRW Position: Q2 2021 in Review
Picton Mahoney Asset Management sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2021, closing a stake of 187,500 shares — an estimated $153K sold.
Picton Mahoney Asset Management first reported a position in JSPRW in Q1 2020 and held it in 5 quarters. The position peaked at $272K in Q4 2020. 20 funds tracked by Wall St. Rank hold JSPRW as of Q2 2021.
- Picton Mahoney Asset Management reported no remaining Japer Therapeutics Warrants position as of Q2 2021 after selling out during the quarter.
- Picton Mahoney Asset Management sold 187,500 Japer Therapeutics Warrants shares in Q2 2021, an estimated $153K.
- Picton Mahoney Asset Management first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 5 quarters.
- Picton Mahoney Asset Management's Japer Therapeutics Warrants position peaked at $272K in Q4 2020.
- 20 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2021.
Based on Picton Mahoney Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.